GLP-3 RT Research Guide: Triple Agonist in Metabolic Studies
GLP-3 RT is the most-discussed metabolic research peptide of the last 24 months.
What is GLP-3 RT?
GLP-3 RT (LY3437943) is an investigational peptide developed by Eli Lilly that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is one of the most actively studied molecules in current metabolic-disease research literature.
Published clinical studies report a circulating half-life of approximately 6 days.
Mechanism of action
The combined triple action is the proposed reason Phase 2 trial data showed substantially greater weight-loss signals than dual or single agonists at comparable durations.
Published clinical data
A Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) reported mean weight reductions in adults with obesity that exceeded those seen with semaglutide and tirzepatide at 48 weeks. Phase 3 trials are ongoing.
Sourcing & purity
Research-grade GLP-3 RT should be at least 99% pure by HPLC, with peptide content verified by mass spectrometry. Redline Bio GLP-3 RT ships with batch documentation; independent COAs are published to the lab reports page as third-party testing completes.
Compliance reminder
GLP-3 RT is an investigational compound. It is not approved by the FDA for human use, and Redline Bio sells it for laboratory research use only. Researchers are responsible for compliance with all applicable regulations.
Frequently asked questions
What makes GLP-3 RT different from GLP-1 S or GLP-2 T?
GLP-1 S is a single GLP-1 receptor agonist. GLP-2 T is a dual GLP-1/GIP agonist. GLP-3 RT adds a third arm: glucagon receptor agonism. This triple action is the basis for the larger weight-loss signals seen in its published Phase 2 trial data.
What is the half-life of GLP-3 RT?
Published Phase 1 pharmacokinetic data places the half-life at approximately 6 days, which corresponds to the weekly sampling interval used in the published clinical literature.